Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Reaches New 1-Year Low – Here’s What Happened

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRYGet Free Report) reached a new 52-week low on Wednesday . The stock traded as low as $4.92 and last traded at $4.92, with a volume of 1992218 shares changing hands. The stock had previously closed at $5.03.

Wall Street Analyst Weigh In

Separately, Bank of America upgraded Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Bayer Aktiengesellschaft has a consensus rating of “Hold”.

View Our Latest Analysis on Bayer Aktiengesellschaft

Bayer Aktiengesellschaft Stock Performance

The stock has a 50-day moving average of $5.89 and a 200 day moving average of $6.95. The firm has a market capitalization of $19.29 billion, a P/E ratio of -18.88 and a beta of 1.03. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.81 and a current ratio of 1.32.

Bayer Aktiengesellschaft (OTCMKTS:BAYRYGet Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.10). The company had revenue of $10.96 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. On average, research analysts anticipate that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

(Get Free Report)

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

Featured Articles

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.